BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States
ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a…
Month: December 2022
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc….
X4 Pharmaceuticals Prices $65.0 Million Public Offering
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv,…
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE…
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) — via InvestorWire — India Globalization Capital, Inc…
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
— Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course…
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
Newly issued patent expires in 2040 BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — VYNE…
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in…
BetterLife Announces Closing of Private Placement
VANCOUVER, British Columbia, Dec. 07, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Piiano Equips Developers to Stop Sensitive Data Breaches
Data protection company Piiano officially launches a vault for sensitive customer data, the first among…
RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA…
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
DMPK Transcript Levels Figure 1. No significant changes in mean DMPK transcript levels were observed…
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
BioVie Issues Letter to Shareholders
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase…
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment…
Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io
– Dante Genomics uses the 1health.io platform to accelerate their go to market strategy and…
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
DURHAM, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) — Atsena Therapeutics, a clinical-stage gene therapy company…
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains…